Avonex, Interferon Beta-1a News

Biogen Idec Inc ., a Cambridge company known for its multiple sclerosis drugs, said that US Food and Drug Administration has granted it Fast Track designation for a potential treatment of relapsing multiple sclerosis.

It wasn't the acquisition some investors had hoped for, but Acorda Therapeutics Inc.

NEW NEW Abstract Background Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.

JERUSALEM Two drug makers announced Thursday that they have finished enrolling patients in a phase 3 clinical trial to evaluate a drug for treating relapsing-remitting multiple sclerosis.

Jun 22, 2009 - Biogen Idec today announced enrollment of the first patient in a Phase III, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of PEGylated interferon beta-1a in patients with relapsing multiple sclerosis .

The European Medicines Agency has been formally notified by BioPartners GmbH of its decision to withdraw its application for Biferonex , 6 million-international-unit solution for injection, prefilled syringes for subcutaneous administration.

Myth: MS can be cured. Fact: There is currently no cure for MS. You may see websites or ads for herbal products, supplements, or other treatments that claim to cure MS.

May 26, 2009 - Biogen Idec today announced that it has sent to its stockholders a letter urging them to vote Biogen Idec's WHITE proxy card FOR all of the Company's Board of Directors' highly regarded and experienced nominees.

More than 11,000 neurologists, investigators and trainees gathered in Seattle in late April for the 2009 annual meeting of the American Academy of Neurology, one of this country's top venues for sharing clinical research progress related to multiple sclerosis and other neurological disorders.

Medications for multiple sclerosis play an important role in the management of MS.

Wednesday May 13, 2009 For people taking a multiple sclerosis treatment using interferon beta-1a , combining it with oral methylprednisolone may improve outcomes for relapsing-remitting MS.

In patients with relapsing-remitting multiple sclerosis, adding oral methylprednisolone to treatment with interferon beta-1a can significantly reduce the rate of relapse, according to a report in the April 30th online issue of The Lancet Neurology.

Editor's Choice Main Category: Multiple Sclerosis Article Date: 05 May 2009 - 0:00 PDT Conclusions reported in an Article published Online first, as well as in the June edition of The Lancet Neurology , and the announcement made at the American Academy of Neurology meeting in Seattle, USA, all coincide that the substantial decline of the ...

In multiple sclerosis, mitoxantrone treatment is associated with a higher-than-expected risk of leukemia, but combined treatment with methylprednisolone and interferon-beta 1a is associated with more beneficial effects on disease activity than interferon alone, according to two studies presented at the annual meeting of the American Academy of ...

New Phase III results presented at the American Academy of Neurology congress show that 80-83% of patients taking FTY720 , an investigational oral compound for relapsing-remitting multiple sclerosis, remained free of relapses during the one-year study compared to 69% of those on interferon beta-1a[2], an established standard of care[3] [2]. The ...

De afkorting CHAMPIONS staat - 05/01/2009 - 06:33 AM DUBLIN-- --Research and Markets has announced the addition of the "LTE: 4G Mobile Broadband Development" report to their offering.

April 30, 2009 - Biogen Idec today announced data results from the CHAMPIONS Multiple Sclerosis Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS .

New Phase III results presented at the American Academy of Neurology congress show that 80-83% of patients taking FTY720 *, an investigational oral compound for relapsing-remitting multiple sclerosis, remained free of relapses during the one-year study compared to 69% of those on interferon beta-1a[2], an established standard of care[3] . These ...

Biogen Idec Inc. beat analyst expectations for earnings in the first quarter of 2009, but product revenues fell short across the board, and Tysabri once again showed slower-than-anticipated growth.

Apr 15, 2009 - Biogen Idec today announced that 25 company-sponsored platform and poster presentations will take place during the 61st Annual Meeting of the American Academy of Neurology in Seattle, WA, April 25 through May 2, 2009.